Skip to main content

RegMedNet is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Journal
    • Our Journals
    • Journal content
    • Journal articles

    Follow us on social media

  • News
  • Topics
    • CAR-T
      • Stem cells
      • Cell therapy
      • Gene therapy
      • Gene editing
    • Cancer
      • Preclinical research
      • Tissue engineering
      • 3D printing
      • Biobanking
    • Clinical trials & funding
      • Manufacturing & scale-up
      • Regulation & policy
      • Industry developments

    Follow us on social media

  • Features
    • The week in cell therapy
      • Spotlights
      • In Focus
      • Tech digest
    • Interviews
      • Opinion
      • Report
      • App Notes & White Papers
    • Find a partner
      • Events
      • Events coverage
      • The Glossary for Advanced Therapies

    Follow us on social media

  • Multimedia
    • eBooks
    • Webinars
    • Podcasts
    • Videos
    • Infographics

    Follow us on social media

  • Register
Spotlight exclusive: Expert insights on GMP media, xeno-free solutions and raw material management Read the interview!

RegMedNet at ISCT 2017

16 May 2017
Written by RegMedNet
Cell therapy Report Spotlight on cell therapy regulation Upcoming & past events

RegMedNet brings you a roundup of the hot topics from the International Society for Cellular Therapy (ISCT)’s 23rd Annual Meeting in London, UK.

Discover what presentations were the most popular during the 4 days of ISCT 2017, what was exhibited and who attended.

Did you attend ISCT 2017? What did you enjoy most?

Where would you like to meet RegMedNet and Regenerative Medicine next?

Top content

  • Gene therapy eases muscle spasticity caused by spinal cord injury
  • Novel gene therapy platform shows promise in Duchenne muscular dystrophy preclinical model

Related tags

ISCT
Previous article Next article

Related articles

14 APR 2026 UPCOMING & PAST EVENTS
Our top picks for ISCT 2026
5 MAY 2018 REPORT
ISCT 2018: highlights in brief
2 JUN 2020 CELL THERAPY
Going virtual for ISCT 2020: an interview with John Rasko
computer-generated image of a virus
10 JUN 2020 COVID-19
COVID-19 and cell therapy: an interview with Daniel Weiss
24 MAR 2020 CELL THERAPY
ISCT transitions to a virtual conference amidst coronavirus concerns
5 FEB 2019 CELL THERAPY
Keeping patients safe from unproven cell therapies: an interview with the ISCT Presidential Task Force on the Use of Unproven and/or Unethical Cell and Gene Therapies
  • About
  • Contact Us
  • Advertising & Sponsorship
  • Expert Panel
  • The Glossary for Advanced Therapies
  • Permissions & content ownership policy
  • Accessibility
  • Editorial Policies

Contact

Contact Us

Office info

RegMedNet is powered by Taylor & Francis Group

RegMedNet, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 RegMedNet